The company reported total operating expenses at USD2.7m for the second fiscal quarter ended 31 July 2019 against the total operating expenses of USD4.5m in the year-ago period.

The firm posted net loss for the fiscal quarter ended 31 July 2019 at USD2.6m compared with a net loss of USD4.4m in the same period in 2018.

'This was an important quarter for BioPharmX to position our late-stage product candidates for continued success. We were extremely pleased to deliver positive Phase 2b trial results for BPX-04 as well as to secure additional patent protection for the underlying technology,' said Dr Tierney, BioPharmX CEO.